Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer

Cited by (1,003)

Items 801–900 of 1,003

1. Blood-based tumor mutational burden impacts clinical outcomes of immune checkpoint inhibitor treated breast and prostate cancers
   Reagan M. Barnett, Albert Jang, Sree Maunika Lanka, Pingfu Fu, Leslie A. Bucheit, Hani M. Babiker, Alan Haruo Bryce, Haley M. Meyer, Yujin Choi, Casey Moore et al. · 2024 · Communications Medicine
2. What Is Known about Theragnostic Strategies in Colorectal Cancer
   Alessandro Parisi, Giampiero Porzio, Fanny Pulcini, Katia Cannita, Corrado Ficorella, Vincenzo Mattei, Simona Delle Monache · 2021 · Biomedicines
3. The circulating soluble form of the CD40 costimulatory immune checkpoint receptor and liver metastasis risk in rectal cancer
   Sebastian Meltzer, Annette Torgunrud, Hanna Abrahamsson, Arne Mide Solbakken, Kjersti Flatmark, Svein Dueland, Kine Mari Bakke, Paula Anna Bousquet, Anne Negård, Christin Johansen et al. · 2021 · British Journal of Cancer
4. Recent advances in primary resistance mechanisms against immune checkpoint inhibitors
   Yi-Ze Li, Hong-Mei Zhang · 2021 · Current Opinion in Oncology
5. Microsatellite instability and chemosensitivity in solid tumours
   Sara Cherri, Ester Oneda, Silvia Noventa, Laura Melocchi, Alberto Zaniboni · 2022 · Therapeutic Advances in Medical Oncology
6. Pan-cancer molecular tumor board experience with biomarker-driven precision immunotherapy
   Bryan H. Louie, Shumei Kato, Ki Hwan Kim, Hyo Jeong Lim, Ryosuke Okamura, Ramez Nassef Eskander, Gregory P. Botta, Hitendra Patel, Suzanna Lee, Scott Michael Lippman et al. · 2022 · npj Precision Oncology
7. Immunoregulatory signal networks and tumor immune evasion mechanisms: insights into therapeutic targets and agents in clinical development
   Qian Wei, Kjetil Taskén · 2022 · Biochemical Journal
8. Identification and validation of transferrin receptor protein 1 for predicting prognosis and immune infiltration in lower grade glioma
   Hongrong Wu, Haoyang He, Jiexiong Huang, Chuan Wang, Yuejiao Dong, Ruilin Lin, Zhuofeng Cheng, Qiancheng Qiu, Liangli Hong · 2022 · Frontiers in Molecular Neuroscience
9. Colorectal cancer: Review of signaling pathways and associated therapeutic strategies
   Premila Devi Leiphrakpam, Senthil Jagannathan Rajappa, Mridula Krishnan, Rishi Batra, Shilpa Shree Murthy, Chandrakanth Are · 2023 · Journal of Surgical Oncology
10. Immunotherapy in the Management of Esophagogastric Cancer: A Practical Review
    Sunita Patruni, Fatima Fayyaz, Jeffrey Y. Bien, T. Waalkes Phillip, Daniel A. King · 2022 · JCO Oncology Practice
11. Consensus Molecular Subtypes as Biomarkers of Fluorouracil and Folinic Acid Maintenance Therapy With or Without Panitumumab in <i>RAS</i> Wild-Type Metastatic Colorectal Cancer (PanaMa, AIO KRK 0212)
    Stahler, Arndt, Hoppe, Beeke, Na, Il-Kang, Keilholz, Luisa, Müller, Lothar, Karthaus, Meinolf, Fruehauf, Stefan, Graeven, Ullrich, Fischer von Weikersthal, Ludwig, Goekkurt, Eray et al. · 2023 · Journal of Clinical Oncology
12. Updated outcomes and exploratory analysis of RENMIN-215: tislelizumab plus fruquintinib and fecal microbiota transplantation in refractory microsatellite stable metastatic colorectal cancer
    Wensi Zhao · 2024 · American Journal of Cancer Research
13. Assessment and treatment considerations for patients with colorectal liver metastases: AHPBA consensus guideline and update for surgeons
    Lavanya Yohanathan, Asmita Chopra, Kerri Ann Simo, Thomas E. Clancy, Amit S. Khithani, Daniel A. Anaya, Felipe B. Maegawa, Mohd Raashid Sheikh, Mustafa Raoof, Michael R. Jacobs et al. · 2024 · HPB
14. Rectal cancer - French intergroup clinical practice guidelines for diagnosis, treatment, and follow-up (TNCD, SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, SFP, RENAPE, SNFCP, AFEF, SFR, and GRECCAR)
    Eddy Cotte, Justine Arquilliere, Pascal Artru, Jean‐Baptiste Bachet, Léonor Benhaïm, Frédéric Bibeau, Niki Christou, Thierry Conroy, J. Doyen, Christine Caroline Hoeffel et al. · 2024 · Digestive and Liver Disease
15. Improvement of the Anticancer Efficacy of PD‐1/PD‐L1 Blockade: Advances in Molecular Mechanisms and Therapeutic Strategies
    Peng Gao, Xiao Li, Zhenyu Duan, Yang Wang, Yinggang Li, Jing Wang, Kui Luo, Jie Chen · 2025 · MedComm
16. Durvalumab and tremelimumab plus local partial tumour ablation (radiofrequency ablation or stereotactic radiotherapy) in patients with unresectable liver metastases from metastatic colorectal cancer: results of the EORTC-1560-GITCG multicentre, single-arm phase II study (ILOC)
    Jenny F. Seligmann, Thibaud Koessler, Murielle E.L. Mauer, Serge Évrard, J. Freedman, Elske C. Gootjes, Matthias Gückenberger, Anne-Sophie Govaerts, A. Giraut, Jens Ricke et al. · 2025 · ESMO Open
17. Strategies to Overcome PD-1/PD-L1 Blockade Resistance: Focusing on Combination with Immune Checkpoint Blockades
    Dinglin Liu, Haoyue Xiao, Ying Xiang, Dian Zhong, Yuchen Liu, Yunfei Wang, Weijia Zhang · 2025 · Journal of Cancer
18. Colorectal Cancer in Romania: Surgical Strategies, Survival, and Historical Trends in a 302-Patient Cohort
    Laurențiu Augustus Barbu, Liliana Cercelaru, Valeriu Şurlin, Stelian Ştefăniţă Mogoantă, Tiberiu Ștefăniță Țenea Cojan, Nicolae-Dragoș Mărgăritescu, Ana-Maria Țenea Cojan, Valentina Căluianu, Gabriel Florin Răzvan Mogoș, Liviu Vasile · 2025 · Life
19. Evaluating larotrectinib for the treatment of advanced solid tumors harboring an NTRK gene fusion
    Roberto Filippi, Ilaria Depetris, Maria Antonietta Satolli · 2021 · Expert Opinion on Pharmacotherapy
20. MicroRNAs as Predictive Biomarkers of Resistance to Targeted Therapies in Gastrointestinal Tumors
    Valentina Angerilli, Francesca Galuppini, Gianluca Businello, Luca Dal Santo, Edoardo Vincenzo Savarino, Stefano Realdon, Vincenza Guzzardo, Lorenzo Nicolè, Vanni Lazzarin, Sara Lonardi et al. · 2021 · Biomedicines
21. Pembrolizumab with Capox Bevacizumab in patients with microsatellite stable metastatic colorectal cancer and a high immune infiltrate: The FFCD 1703-POCHI trial
    Claire Gallois, Jean‐François Emile, Stefano Chong Hun Kim, Carole Montérymard, Marine Gilabert, Jérémie Bez, Astrid Lièvre, Laëtitia Dahan, Pierre Laurent‐Puig, Laurent Mineur et al. · 2021 · Digestive and Liver Disease
22. State legislative trends related to biomarker testing
    Gelareh Sadigh, Hilary Gee Goeckner, Ella Annabelle Kazerooni, Bruce Evan Johnson, Robert Allen Smith, Devon V. Adams, Ruth C. Carlos · 2022 · Cancer
23. Integrative molecular profiling identifies two molecularly and clinically distinct subtypes of blastic plasmacytoid dendritic cell neoplasm
    Axel Künstner, Julian Schwarting, Hanno Maximilian Witte, Veronica Bernard, Stephanie Stölting, Kathrin Kusch, Kumar Nagarathinam, Nikolas C. C. von Bubnoff, Eva Maria Murga Penas, Hartmut Merz et al. · 2022 · Blood Cancer Journal
24. The distinct clinical trajectory, metastatic sites, and immunobiology of microsatellite-instability-high cancers
    Shuting Han, Aik Yong Chok, Daniel Yang Yao Peh, Joshua Zhi-Ming Ho, Emile Tan, Si‐Lin Koo, Iain Beehuat Tan, Johnny Chin-Ann Ong · 2022 · Frontiers in Genetics
25. Anti-Programmed Cell Death-1 Antibody and Dasatinib Combination Therapy Exhibits Efficacy in Metastatic Colorectal Cancer Mouse Models
    Hiroki Kadota, Ryo Yuge, Daisuke Shimizu, Ryo Miyamoto, Rina Otani, Yuichi Hiyama, Hidehiko Takigawa, Ryohei Hayashi, Yuji Urabe, Yasuhiko Kitadai et al. · 2022 · Cancers
26. Identification and characterization of circular RNAs as novel putative biomarkers to predict anti-PD-1 monotherapy response in metastatic melanoma patients – Knowledge from two independent international studies
    Jian‐Guo Zhou, Rui Liang, Hai-Tao Wang, Su‐Han Jin, Wei Hu, Benjamin Frey, Rainer Fietkau, Markus Hecht, Hu Ma, Udo S. Gaipl · 2023 · Neoplasia
27. Inflammation, Infiltration, and Evasion—Tumor Promotion in the Aging Breast
    Nicole Cruz-Reyes, Derek C. Radisky · 2023 · Cancers
28. Pan-cancer analysis reveals IGFL2 as a potential target for cancer prognosis and immunotherapy
    Yuqi Wang, Hongwei Yuan, Genquan Yue, Lingyan Zhao, Yuan Xia, Nan Zhang, Hailing Li, Dongyang Liu, Yubo Su, Haisheng Wang et al. · 2023 · Scientific Reports
29. Intrinsic features of the cancer cell as drivers of immune checkpoint blockade response and refractoriness
    Chiara Ursino, Cécile Mouric, Laurent Gros, Nathalie Bonnefoy, Julien Faget · 2023 · Frontiers in Immunology
30. Immune checkpoint blockade therapy for BRAF mutant metastatic colorectal cancer: the efficacy, new strategies, and potential biomarkers
    Jie Zhong, Zijian Sun, Sheng Li, Yang Liu, Yuepeng Cao, Jun Bao · 2023 · Discover Oncology
31. Molecular and genetic targets within metastatic colorectal cancer and associated novel treatment advancements
    Christopher Cann, Michael Brian LaPelusa, Sarah K Cimino, Cathy Eng · 2023 · Frontiers in Oncology
32. Immunotherapy in urothelial cancer: current status and future directions
    Claudia Piombino, Elena Tonni, Marco Oltrecolli, Marta Pirola, Stefania Pipitone, Cinzia Baldessari, Massimo Dominici, Roberto Sabbatini, Maria Giuseppa Vitale · 2023 · Expert Review of Anticancer Therapy
33. Research on radiotherapy related genes and prognostic target identification of rectal cancer based on multi-omics
    Yi Liu, Yanguang Yang, Feng Ni, Guomei Tai, Cenming Yu, Xiaohui Jiang, Ding Wang · 2023 · Journal of Translational Medicine
34. Predictive response and outcome of peripheral CD4+ T cell subpopulations to combined immunotherapy and chemotherapy in advanced gastric cancer patients
    Deyu Gao, Liqiong Liu, Jianhua Liu, Jiang Liu · 2024 · International Immunopharmacology
35. The future of cancer vaccines against colorectal cancer
    Wenqing Jia, Xiaonan Shen, Zichao Guo, Xi Cheng, Ren Zhao · 2024 · Expert Opinion on Biological Therapy
36. NUP43 promotes PD-L1/nPD-L1/PD-L1 feedback loop via TM4SF1/JAK/STAT3 pathway in colorectal cancer progression and metastatsis
    Fan Wu, Guoqiang Sun, Yongjun Nai, Xuesong Shi, Yong Ma, Hongyong Cao · 2024 · Cell Death Discovery
37. Advancements in colorectal cancer immunotherapy: from CAR-T cells to exosome-based therapies
    Sepideh Arabi, Manouchehr Fadaee, Tohid Kazemi, Mohammad Reza Rahmani · 2025 · Journal of drug targeting
38. Promising Cellular Immunotherapy for Colorectal Cancer Using Classical Dendritic Cells and Natural Killer T Cells
    Mahmoud Singer, Jennifer Brooke Valerin, Zhuoli Zhang, Zigeng Zhang, Farshid Dayyani, Vahid Yaghmai, April Choi, David K. Imagawa, Nadine Abi‐Jaoudeh · 2025 · Cells
39. New first-line therapy for dMMR/MSI-H CRC
    Diana Romero · 2020 · Nature Reviews Clinical Oncology
40. Microsatellite instability (MSI-H) is associated with a high immunoscore but not with PD-L1 expression or increased survival in patients (pts.) with metastatic colorectal cancer (mCRC) treated with oxaliplatin (ox) and fluoropyrimidine (FP) with and without bevacizumab (bev): a pooled analysis of the AIO KRK 0207 and RO91 trials
    Stefanie Nöpel‐Dünnebacke, Hendrik Juette, Karsten Schulmann, U. Graeven, Rainer Porschen, Jan Stoehlmacher, Susanna Hegewisch‐Becker, Arne Raulf, Dirk Arnold, Anke Reinacher‐Schick et al. · 2021 · Journal of Cancer Research and Clinical Oncology
41. Update on the role of pembrolizumab in patients with unresectable or metastatic colorectal cancer
    Vanessa Wookey, Axel F. Grothey · 2021 · Therapeutic Advances in Gastroenterology
42. Immune checkpoint inhibitor-mediated colitis in gastrointestinal malignancies and inflammatory bowel disease
    Alexa R. Weingarden, Samuel J. S. Rubin, John Mark B. Gubatan · 2021 · World Journal of Gastrointestinal Oncology
43. Innate lymphoid cells in colorectal cancer
    Anne Marchalot, Jenny Mjösberg · 2022 · Scandinavian Journal of Immunology
44. Discovery and pharmacological characterization of cetrelimab (JNJ-63723283), an anti–programmed cell death protein-1 (PD-1) antibody, in human cancer models
    Nikki DeAngelis, Catherine A. Ferrante, Gordon D. Powers, Jocelyn Andrel Sendecki, Bethany K. Mattson, Darlene Pizutti, Kathryn E. Packman, Weirong Wang, Kevin Trouba, Rupesh K. Nanjunda et al. · 2022 · Cancer Chemotherapy and Pharmacology
45. Benefit from upfront FOLFOXIRI and bevacizumab in BRAFV600E-mutated metastatic colorectal cancer patients: does primary tumour location matter?
    Roberto Moretto, Andrew Elliott, Daniele Rossini, Rossana Intini, Veronica Conca, Filippo Pietrantonio, Andrea Sartore Bianchi, Carlotta Antoniotti, Cosimo Rasola, Mario Scartozzi et al. · 2022 · British Journal of Cancer
46. Immunotherapy in colorectal cancer: an unmet need deserving of change
    Elena Élez, Iosune Baraibar · 2022 · The Lancet Oncology
47. Patients deriving long-term benefit from immune checkpoint inhibitors demonstrate conserved patterns of site-specific mutations
    Daniel R. Principe · 2022 · Scientific Reports
48. Autologous T cell responses to primary human colorectal cancer spheroids are enhanced by ectonucleotidase inhibition
    Julie Bonnereau, Tristan Courau, Nicolas Asesio, Delphine Salfati, Fatiha Amira Bouhidel, Hélène Corté, Sarah Hamoudi, Nassim Hammoudi, Julie Lavolé, Justine Vivier-Chicoteau et al. · 2022 · Gut
49. Tumor Biomarker Testing for Metastatic Colorectal Cancer: a Canadian Consensus Practice Guideline
    Irene S. Yu, Francine Aubin, Rachel Anne Goodwin, Jonathan M. Loree, Cheryl A. Mather, Brandon S. Sheffield, Stephanie Leann Snow, Sharlene Gill · 2022 · Therapeutic Advances in Medical Oncology
50. Evaluation of immunotherapy efficacy in gynecologic cancer
    Genyi Jiang, Qianhua Wu, Bilan Li · 2023 · Frontiers in Immunology
51. Dostarlimab: From preclinical investigation to drug approval and future directions
    Carlo María Cicala, Lucia Musacchio, Giovanni Scambia, Domenica Lorusso · 2023 · Human Vaccines & Immunotherapeutics
52. Personalized Systemic Therapies in Hereditary Cancer Syndromes
    Luciana Mastrodomenico, Claudia Piombino, B. Riccò, Elena Barbieri, Marta Venturelli, Federico Piacentini, Massimo Dominici, Laura Cortesi, Angela Toss · 2023 · Genes
53. Transarterial Radioembolization in Patients With Unresectable Colorectal Cancer Liver Metastases
    Robert William Lentz, Wells A. Messersmith · 2021 · Journal of Clinical Oncology
54. Sex and outcomes of patients with microsatellite instability-high and BRAF V600E mutated metastatic colorectal cancer receiving immune checkpoint inhibitors
    Vincenzo Nasca, Joseph Jonathan Zhao, Javier Ros, Sara Lonardi, Koen Zwart, Romain Cohen, Marwan Fakih, Priya Jayachandran, Jeanine M.L. Roodhart, Jeroen W. G. Derksen et al. · 2025 · Journal for ImmunoTherapy of Cancer
55. Immune Checkpoint Blockade Therapies for Colorectal Cancer: Current Strategies and Emerging Approaches
    Kelly Pum, Christopher James LaRocca, Paolo Goffredo, Subbaya Subramanian, Emil Lou, Ajay Prakash · 2025 · JCO oncology advances.
56. Of Context, Quality, and Complexity: Fine-Combing Tumor Mutational Burden in Immunotherapy-Treated Cancers
    Noushin Niknafs, Mimi Najjar, Colum Dennehy, Ioannis Stouras, Valsamo Anagnostou · 2025 · Clinical Cancer Research
57. The multifaceted role of microRNAs in colorectal cancer: pathogenesis and therapeutic implications
    Federica Longo, Giuseppe Gattuso, Graziana Spoto, Daria Ricci, Anastasia Cristina Venera Vitale, Alessandro Lavoro, Saverio Candido, Massimo Libra, Luca Falzone · 2025 · Non-coding RNA Research
58. Early-Onset Colorectal Cancer: From Genetic Discovery to Clinical Innovation
    Anita Ahmed Turk, Sebastián Mondaca, Bruno Nervi, Allison D. Morris, Zoe R. Finer, Andreana Natalie Holowatyj · 2025 · American Society of Clinical Oncology Educational Book
59. Prognostic impact of the BRAF V600E mutation in patients with MSI-high metastatic colorectal cancer treated with immune checkpoint inhibitors
    Claire Gallois, Margherita Ambrosini, Sara Lonardi, Emily Linda Alouani, Rosine Guimbaud, Michael James Overman, Frank A. Sinicrope, Thibault Mazard, Marie Decraecker, Javier Ros et al. · 2025 · European Journal of Cancer
60. Role of S-palmitoylation in digestive system diseases
    Hanqing Li, Qiuxiang Yuan, Shuangshuang Wang, Tao Yu, Xingsi Qi · 2025 · Cell Death Discovery
61. Neoadjuvant immunotherapy for nonmetastatic dMMR/MSI colon cancer: a real-world retrospective AGEO study
    C. Lemaire, A. Boileve, Gilles Manceau, Clélia Coutzac, Marie Müller, Paul Girot, Lisa Lellouche, Aurélien Saltel-Fulero, Christine Lagorce, Claire Gallois et al. · 2025 · ESMO Open
62. Synergistic H&E and IHC image analysis by AI predicts cancer biomarkers and survival outcomes in colorectal and breast cancer
    Yating Cheng, Norsang Lama, Ming Chen, Eghbal Amidi, Mohammadreza Ramzanpour, Md. Samiur Rahman, Joanne Xiu, Anthony Helmstetter, Lauren R. Dickman, Jennifer R. Ribeiro et al. · 2025 · Communications Medicine
63. KDM4A-induced tumor senescence enhances the efficacy of immunotherapy by inhibiting AGT-PHB1 axis-mediated mitophagy in colorectal cancer
    Tanxing Cai, Zhenxing Liang, Zhiping Chen, Yang Li, Wei Xiao, Wenfeng Liang, Hao Xie, Huashan Liu, Ziwei Zeng, Xin Yang et al. · 2025 · Autophagy
64. PLGA-based nanoparticles in colorectal cancer immunotherapy: current concepts and future perspectives
    Yuhan Wang, Peng Huang, Chun Li, Shengjin Tu, Hua Yang · 2025 · Frontiers in Pharmacology
65. Immune escape in colorectal cancer: Mechanisms and challenges of immune checkpoint inhibitor resistance
    Mohammad Yousefi, Danial Gharaie, Mohammad Reza Javan, Arezou Khosrojerdi · 2025 · International Immunopharmacology
66. Neoadjuvant Therapy for Rectal Cancer
    Felipe Quezada-Díaz, Jesse Joshua Smith · 2022 · Surgical Oncology Clinics of North America
67. PD-1 Blockade Combined with Heated Intraperitoneal Chemotherapy Improves Outcome in Experimental Peritoneal Metastases from Colonic Origin in a Murine Model
    Ravit Geva, Gilad Alon, Maya Nathanson, Shoshi Bar-David, Nadav Nevo, Asaf Aizic, Sharon Peles-Avraham, Guy Lahat, Eran Nizri‏ · 2023 · Annals of Surgical Oncology
68. Guidance for Treating the Older Adults with Colorectal Cancer
    Dina Ioffe, Efrat Dotan · 2023 · Current Treatment Options in Oncology
69. Outcome of Patients With Early-Stage Mismatch Repair Deficient Colorectal Cancer Receiving Neoadjuvant Immunotherapy: A Systematic Review
    Sakti Chakrabarti, Udhayvir Singh Grewal, Kruti Bhagirath Vora, Aparna R. Parikh, Diana Almader‐Douglas, Amit Mahipal, Mohamad Bassam Sonbol · 2023 · JCO Precision Oncology
70. Impact of formalin fixation on mismatch repair protein evaluation by immunohistochemistry
    Federica Grillo, Murad Hayatt Ali, Michele Paudice, Simona Pigozzi, Giorgia Anselmi, Stefano Scabini, Stefania Sciallero, Nataniele Piol, Luca Mastracci · 2023 · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin
71. Immunocheckpoint Inhibitors in Microsatellite-Stable or Proficient Mismatch Repair Metastatic Colorectal Cancer: Are We Entering a New Era?
    Laura Matteucci, Alessandro Bittoni, Graziana Gallo, Laura Ridolfi, Alessandro Passardi · 2023 · Cancers
72. The tumor immune microenvironment in pancreatic cancer and its potential in the identification of immunotherapy biomarkers
    Ryouichi Tsunedomi, Yoshitaro Shindo, Masao Nakajima, Kiyoshi Yoshimura, Hiroaki Nagano · 2023 · Expert Review of Molecular Diagnostics
73. Comprehensive genomic profiling reveals prognostic signatures and insights into the molecular landscape of colorectal cancer
    Jinwei Yang, Sihui Zhao, Junyan Su, Siyao Liu, Zaozao Wu, Wei Ma, Ming Tang, Jingcui Wu, Erdong Mao, Han Li et al. · 2023 · Frontiers in Oncology
74. Improving the efficiency of immune checkpoint inhibitors for metastatic pMMR/MSS colorectal cancer: Options and strategies
    Changjiang Yang, Long Zhao, Yilin Lin, Shan Wang, Yingjiang Ye, Zhanlong Shen · 2023 · Critical Reviews in Oncology/Hematology
75. Impact of antihistamine use on the survival outcomes of immune checkpoint inhibitors in advanced cancer patients
    Eda Eylemer Mocan, Emre Yekedüz, Emre Yekedüz, Göktürk Karataş, Satı Coşkun Yazgan, Elif Berna Köksoy, F. Cay Senler, Güngör Utkan, Ahmet Demirkazık, Hakan Akbulut et al. · 2023 · Anti-Cancer Drugs
76. CHEK2 deficiency increase the response to PD-1 inhibitors by affecting the tumor immune microenvironment
    Pingping Xu, Yaqi Gao, Shanshan Jiang, Yun Cui, Yuanhong Xie, Zi‐Ran Kang, Yingxuan Chen, Danfeng Sun, Jing‐Yuan Fang · 2023 · Cancer Letters
77. Recent updates in the therapeutic uses of Pembrolizumab: a brief narrative review
    Vítor Silva, Cristiano Matos · 2024 · Clinical & Translational Oncology
78. Fertility in young-onset colorectal patients with cancer: a review
    Qiuping Jiang, Hongmei Hua · 2024 · The Oncologist
79. Mechanism of immune activation mediated by genomic instability and its implication in radiotherapy combined with immune checkpoint inhibitors
    Siwei Wang, Qiu-Yi Zheng, Wei-Feng Hong, Bufu Tang, Shu-Jung Hsu, Yang Zhang, Xiaobin Zheng, Zhao-Chong Zeng, Chao Gao, Ai‐Wu Ke et al. · 2024 · Radiotherapy and Oncology
80. DDR1 is identified as an immunotherapy target for microsatellite stable colon cancer by CRISPR screening
    Miaoqing Wu, Wenjuan Ma, Guangzhao Lv, Xin Wang, Cong Li, Xiang Chen, Xiaofei Peng, Chaoming Tang, Zhizhong Pan, Ranyi Liu et al. · 2024 · npj Precision Oncology
81. Association of the Lung Immune Prognostic Index with Immunotherapy Outcomes in Mismatch Repair Deficient Tumors
    Édouard Auclin, Perrine Vuagnat, Cristina Smolenschi, Julien Taı̈eb, Jorge Adeva, Laëtitia Nebot-Bral, Marta García de Herreros, Rosario Vidal Tocino, Federico Longo-Muñoz, Yola El Dakdouki et al. · 2021 · Cancers
82. Precision Medicine for Colorectal Cancer with Liquid Biopsy and Immunotherapy
    Satoshi Nagayama, Siew‐Kee Low, Kazuma Kiyotani, Yusuke Nakamura · 2021 · Cancers
83. Local Treatments in the Unresectable Patient with Colorectal Cancer Metastasis: A Review from the Point of View of the Medical Oncologist
    Javier Torres-Jiménez, Jorge Esteban-Villarrubia, Reyes Ferreiro, Alfredo Carrato · 2021 · Cancers
84. CANDIED: A Pan-Canadian Cohort of Immune Checkpoint Inhibitor-Induced Insulin-Dependent Diabetes Mellitus
    Thiago Pimentel Muniz, Daniel Vilarim Araújo, Kerry J. J. Savage, Tina Cheng, Moumita Saha, Xinni Song, Sabrina Gill, Jose Gerard Monzon, Debjani Grenier, Sofia Genta et al. · 2021 · Cancers
85. A novel senescence-associated LncRNA signature predicts the prognosis and tumor microenvironment of patients with colorectal cancer: a bioinformatics analysis
    Enmin Huang, Tao Ma, Junyi Zhou, Ning Ma, Wei-Sheng Yang, Chuangxiong Liu, Zehui Hou, Shuang Chen, Zhen Zong, Bing Zeng et al. · 2022 · Journal of Gastrointestinal Oncology
86. GITR Ligation Improves Anti-PD1-Mediated Restoration of Human MMR-Proficient Colorectal Carcinoma Tumor-Derived T Cells
    Yannick Sebastiaan Rakké, Lucia Campos Carrascosa, Adriaan A. van Beek, Valeska de Ruiter, Rachelle S. van Gemerden, Michail Doukas, Pascal Gabriël Doornebosch, Maarten Vermaas, Susan ter Borg, Erwin van der Harst et al. · 2022 · Cellular and Molecular Gastroenterology and Hepatology
87. The Role of Biomarkers in the Management of Colorectal Liver Metastases
    Daniel Brock Hewitt, Zachary J. Brown, Timothy Michael Pawlik · 2022 · Cancers
88. Neoadjuvant PD-1 blockade: a promising nonoperative strategy for mismatch repair–deficient, locally advanced rectal cancer
    Mi Mi, Chenyang Ye, Ying Yuan · 2022 · Signal Transduction and Targeted Therapy
89. Efficacy of regorafenib combined with PD-1 inhibitors in elderly patients with advanced metastatic colorectal cancer
    Beibei Chen, Huichen Zhao, Jinxi Huang, Huifang Lv, Weifeng Xu, Caiyun Nie, Jianzheng Wang, Jing Zhao, Yunduan He, Saiqi Wang et al. · 2022 · BMC Geriatrics
90. Long-term benefit of immunotherapy in a patient with squamous lung cancer exhibiting mismatch repair deficient/high microsatellite instability/high tumor mutational burden: A case report and literature review
    Na Li, Zixuan Wan, Dongyan Lu, Ruilian Chen, Xiaowei Ye · 2023 · Frontiers in Immunology
91. Neoadjuvant immune checkpoint inhibition in the management of glioblastoma: Exploring a new frontier
    Stephen C. Frederico, Corbin Darling, John P. Bielanin, Alexandra C. Dubinsky, Xiaoran Zhang, Constantinos G. Hadjipanayis, Gary Kohanbash · 2023 · Frontiers in Immunology
92. Drug-Induced Liver Injury due to Biologics and Immune Check Point Inhibitors
    Fernando Bessone, Einar Stefan Bjornsson · 2023 · Medical Clinics of North America
93. Immunotherapy Management in Special Cancer Patient Populations
    Brian Hemendra Ramnaraign, Jonathan Alexander Chatzkel, Zeina Al‐Mansour, Sherise Chantell Rogers, Dennie V. Jones, David L. DeRemer, Thomas J. George · 2021 · JCO Oncology Practice
94. Human Epidermal Growth Factor Receptor 2–Targeting Approaches for Colorectal Cancer: Clinical Implications of Novel Treatments and Future Therapeutic Avenues
    Canan Karan, Elaine S Tan, Humaira Rise Sarfraz, Todd Cory Knepper, Christine Marie Walko, Seth I. Felder, Richard D. Kim, İbrahim Halil Şahin · 2022 · JCO Oncology Practice
95. Unleashing the power of anti-HER2 therapies in metastatic colorectal cancer: paving the way for a brighter future
    Babkoff, A., Zick, A., Hubert, A., Tarantino, P., Grinshpun, A. · 2024 · ESMO Gastrointestinal Oncology
96. High tumor mutation burden (TMB) in microsatellite stable (MSS) colorectal cancers: Diverse molecular associations point to variable pathophysiology
    Voutsadakis, Ioannis A. · 2023 · Cancer Treatment and Research Communications
97. Comparative effectiveness of immunotherapy and chemotherapy in patients with metastatic colorectal cancer stratified by microsatellite instability status
    Chengu Niu, Jing Zhang, Aniket-Vijay Rao, Utsav Joshi, Patrick I. Okolo III · 2024 · World Journal of Clinical Oncology
98. Protein arginine methyltransferase 6 enhances immune checkpoint blockade efficacy via the STING pathway in MMR-proficient colorectal cancer
    Jinlin Duan, Tao Chen, Qiwei Li, Yu Zhang, Ting Lu, Junyan Xue, Yang Sun, Ling Gao, Yonglong Zhang · 2025 · Journal for ImmunoTherapy of Cancer
99. Focus on PD-1/PD-L1-Targeting Antibodies in Colorectal Cancer: Are There Options Beyond Dostarlimab, Nivolumab, and Pembrolizumab? A Comprehensive Review
    Mateusz Kciuk, Katarzyna Wanke, Weronika Kruczkowska, Beata Marciniak, Renata Kontek · 2025 · Molecules
100. Modulation of fibronectin extracellular matrix enhances anti-tumor efficacy of immune checkpoint blockade
     Kabir A. Khan, Maresa Caunt, William Cruz‐Muñoz, Grant Li, Patricia Himmels, Ping Xu, Hung Yang Kuo, Rajiv Jesudason, Alvin Gogineni, Robby M. Weimer et al. · 2025 · Cell Reports Medicine